Skip to main content
search
                   

Anca Vasculitis Clinical Trials in Oklahoma City, OK

Join Clinical Trials on (ANCA) Antineutrophil Cytoplasmic Antibody-Associated Vasculitis and help shape the future of chronic disease care.

Enroll Now

If You Have Been Living With ANCA-Associated Vasculitis

This ANCA-Associated Vasculitis Clinical Trial Might Be for You

ANCA-associated vasculitis causes inflammation and damage to blood vessels, affecting vital organs like the kidneys, lungs, and skin. While treatments exist, there is still a need for long-term solutions to better manage the condition and prevent organ damage.

At Hightower, we’re conducting clinical trials to assess the long-term safety of study drug, a promising medication aimed at reducing inflammation and improving disease management in individuals with ANCA-associated vasculitis.

Participation in the Clinical Trial is completely free and voluntary.

To join, simply fill out the form, and a member of our research team will contact you to determine your eligibility.

Study Information

Anca Vasculitis

Study NameProtocol NumberSponsor
Anca Vasculitis

20220159

Amgen

About ANCA Vasculitis Clinical Trials in Oklahoma City, OK

ANCA-associated vasculitis (AAV) is a group of autoimmune diseases characterized by inflammation and damage to blood vessels, particularly in organs like the kidneys, lungs, and skin.

The primary objective of ANCA vasculitis clinical trial is to evaluate the long-term safety of an investigational drug, designed to reduce inflammation by targeting specific immune system pathways.

Participants in this study will receive the study drug over an extended period to assess its safety and effectiveness in managing the condition. This study is crucial for understanding how long-term treatment can help patients with AAV maintain disease remission and avoid organ damage.

*If you have been diagnosed with ANCA-associated vasculitis and meet the eligibility criteria, participating in this trial could provide access to advanced treatment options. *

*Participation in the clinical trials is completely voluntary*

ANCA-Associated Vasculitis Research: What to Expect?

Participating in the ANCA-associated vasculitis research involves routine check-ups, medication administration, and ongoing monitoring of your health and immune response. The trial focuses on ensuring the long-term safety of the study drug while providing close medical supervision from a team of specialists.

During the study, you will regularly meet with healthcare professionals to track your progress. Blood tests, imaging, and other health assessments will help determine how the study drug is affecting your condition. The ultimate goal is to see if the treatment can safely control inflammation without serious side effects.

*This study aims to improve the lives of individuals suffering from AAV by offering them access to potentially life-changing therapies. *

Age

18 to 100 years (Adults, Older Adults)

Gender

All

Condition

ANCA-Associated Vasculitis

Current Status

Recruiting

What Happens in ANCA-Associated Vasculitis (AAV)?

ANCA-associated vasculitis involves the immune system mistakenly attacking blood vessels, causing inflammation and potential damage to organs. Some common symptoms include:

Early diagnosis and appropriate treatment are crucial for preventing permanent organ damage. Participation in clinical trials like this one offers patients the chance to receive cutting-edge therapies and contribute to research that could benefit future generations.

Complications:

  • Common complications of untreated AAV include
  • Kidney failure
  • lung damage
  • Skin rashes are

Symptoms:

Frequent symptoms of the disease include

  • Fever
  • fatigue
  • weight loss
  • difficulty breathing

FAQs

What is ANCA-associated vasculitis (AAV)?

ANCA-associated vasculitis (AAV) is a group of autoimmune diseases that cause inflammation of small blood vessels, leading to damage in organs such as the kidneys, lungs, and skin. This inflammation is caused by an abnormal immune response, where the body’s immune system mistakenly attacks healthy tissues.

What is the purpose of this clinical trial?

The primary objective of this trial is to evaluate the long-term safety of study drug, a medication that targets specific immune pathways to reduce inflammation in patients with ANCA-associated vasculitis (AAV). The study aims to ensure that study drug can help control the disease safely over an extended period.

Who is eligible to participate in the study?

To participate in this study, you must be diagnosed with ANCA-associated vasculitis and be between the ages of 18 and 100. Both men and women are eligible to join, but healthy volunteers without the condition are not accepted.

What can I expect during the study?

If you qualify for the study, you will receive study drug and undergo regular check-ups with healthcare professionals. You’ll be monitored through blood tests, imaging, and other assessments to track your response to the treatment and ensure your safety throughout the trial.

Are there any risks or benefits associated with this trial?

Like all clinical trials, there may be potential risks such as side effects from the medication. However, participants will receive close medical supervision and may benefit from access to advanced treatments that could improve the management of their condition. The study will also help further research on AAV, potentially benefiting future patients.

Close Menu